NK cell‐mediated anti‐tumor immune response to human prostate cancer cell, PC‐3: immunogene therapy using a highly secretable form of interleukin‐15 gene transfer

Interleukin (IL)‐15 is a pleiotropic cytokine that is important forinnate and adaptive immune cell homeostasis. The expression of IL‐15protein is controlled by posttranscriptional mechanisms. Here, weconstructed a human IL‐15 expression vector consisting of the humanIL‐2 signal peptide, the human IL‐15 mature peptide‐coding sequences,and an out‐of‐frame human growth hormone gene. Human prostate cancercells, PC‐3, transfected with this highly secretable form of the IL‐15gene, successfully secreted abundant bioactive IL‐15 protein. In nudemice, the growth of PC‐3 cells producing IL‐15 was remarkably retarded.NK cell‐depletion using anti‐asialo GM1 antibody restoredtumorigenicity. Histologically, tumors derived from IL‐15‐producingPC‐3 cells contained necrotic areas with high apoptotic index.Splenocytes incubated with supernatant of transfectants killed targetPC‐3 cells and expressed a significantly high level of mIFN‐γ mRNA.These observations suggest that NK cell‐mediated, anti‐tumor effects ofIL‐15 could provide a potential rationale for gene therapy of prostatecancer.

[1]  P. Musiani,et al.  Dissimilar anti‐tumour reactions induced by tumour cells engineered with the interleukin‐2 or interleukin‐15 gene in nude mice , 2000, The Journal of pathology.

[2]  P. Morrissey,et al.  Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice , 2000, The Journal of experimental medicine.

[3]  M. Caligiuri,et al.  Cutting Edge: IL-15 Costimulates the Generalized Shwartzman Reaction and Innate Immune IFN-γ Production In Vivo1 , 2000, The Journal of Immunology.

[4]  P. Ohashi,et al.  Differential Roles of Interleukin 15 mRNA Isoforms Generated by Alternative Splicing in Immune Responses in Vivo , 2000, The Journal of experimental medicine.

[5]  B. Foster,et al.  Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  N. Iizuka,et al.  Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo , 1999, British Journal of Cancer.

[7]  Y. Nimura,et al.  Immunogene therapy of murine fibrosarcoma using IL‐15 gene with high translation efficiency , 1999, European journal of immunology.

[8]  M. Caligiuri,et al.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. , 1999, Journal of immunology.

[9]  A. Gaggero,et al.  Differential intracellular trafficking, secretion and endosomal localization of two IL‐15 isoforms , 1999, European journal of immunology.

[10]  J. Rhim,et al.  Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G. Yang,et al.  Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model , 1999, Gene Therapy.

[12]  C. Bucana,et al.  Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. , 1999, Cancer research.

[13]  J. Simons,et al.  Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. , 1998, Seminars in oncology.

[14]  T. Dassopoulos,et al.  IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. , 1998, Immunity.

[15]  J. Sprent,et al.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.

[16]  T. Waldmann,et al.  The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. , 1998, Journal of immunology.

[17]  T. Mak,et al.  The Transcription Factor Interferon Regulatory Factor 1 (IRF-1) Is Important during the Maturation of Natural Killer 1.1+ T Cell Receptor–α/β+ (NK1+ T) Cells, Natural Killer Cells, and Intestinal Intraepithelial T Cells , 1998, The Journal of experimental medicine.

[18]  T. Waldmann,et al.  Requirement for IRF-1 in the microenvironment supporting development of natural killer cells , 1998, Nature.

[19]  Y. Yoshikai,et al.  Translational efficiency is up-regulated by alternative exon in murine IL-15 mRNA. , 1998, Journal of immunology.

[20]  T. Waldmann,et al.  Generation of secretable and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  N. Bander,et al.  MHC class I and II expression in prostate carcinoma and modulation by interferon‐alpha and ‐gamma , 1997, The Prostate.

[22]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[23]  S. Sforzini,et al.  Expression of two interleukin‐15 mRNA isoforms in human tumors does not correlate with secretion: role of different signal peptides , 1997, European journal of immunology.

[24]  C. Croce,et al.  A potential role for interleukin-15 in the regulation of human natural killer cell survival. , 1997, The Journal of clinical investigation.

[25]  T. Pohl,et al.  Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. , 1997, Journal of immunology.

[26]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[27]  T. Waldmann,et al.  Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Waldmann,et al.  IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. , 1996, Immunity.

[29]  M. Caligiuri,et al.  Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. , 1996, Blood.

[30]  M. Caligiuri,et al.  Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. , 1995, The Journal of clinical investigation.

[31]  M. Wick,et al.  Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. , 1995, Cellular immunology.

[32]  R. Dubose,et al.  Identification and cloning of a novel IL‐15 binding protein that is structurally related to the alpha chain of the IL‐2 receptor. , 1995, The EMBO journal.

[33]  K. Pienta,et al.  New treatment strategies for hormone refractory prostate cancer. , 1995, Seminars in urology.

[34]  F. Liew,et al.  Chemoattraction of human blood T lymphocytes by interleukin-15 , 1995, The Journal of experimental medicine.

[35]  M. Sanda,et al.  Molecular characterization of defective antigen processing in human prostate cancer. , 1995, Journal of the National Cancer Institute.

[36]  M. Caligiuri,et al.  Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor , 1994, The Journal of experimental medicine.

[37]  D. Cosman,et al.  Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15. , 1994, The EMBO journal.

[38]  T. Waldmann,et al.  The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  V. Fung,et al.  Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. , 1994, Science.

[40]  W. Isaacs,et al.  Interleukin‐2 transfected prostate cancer cells generate a local antitumor effect in vivo , 1994, The Prostate.

[41]  R. Perlmutter,et al.  Interleukin 4 expressed in situ selectively alters thymocyte development , 1991, The Journal of experimental medicine.

[42]  J. Ritz,et al.  Biology and clinical relevance of human natural killer cells. , 1990, Blood.

[43]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[44]  Management of the Urological Patient , 1977 .

[45]  T. Waldmann,et al.  The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. , 1999, Annual review of immunology.

[46]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[47]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[48]  P. Seeburg.  The human growth hormone gene family: nucleotide sequences show recent divergence and predict a new polypeptide hormone. , 1982, DNA.

[49]  R. Jameson.  Management of the urological patient , 1976 .